Editas Medicine Inc Total Liabilities

Latest as of June 2026: $132.08 Million USD

Editas Medicine Inc total liabilities. Based on the latest financial reports, Editas Medicine Inc (EDIT) has total liabilities worth $132.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Editas Medicine Inc (EDIT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Editas Medicine Inc (2013–2025)

Total liabilities of Editas Medicine Inc from 2013 to 2025. This chart illustrates how Editas Medicine Inc's total liabilities have evolved over time, based on quarterly financial data. Explore EDIT long-term investments to assets to see how much of total assets are deployed in long-term investments.

Editas Medicine Inc Competitors by Total Liabilities

The table below lists competitors of Editas Medicine Inc ranked by their total liabilities.

Company	Country	Total Liabilities
SNDL Inc. NASDAQ:SNDL	USA	$218.77 Million
Hefei Kewell Power System Co Ltd SHG:688551	China	CN¥408.18 Million
VST Industries Limited NSE:VSTIND	India	Rs-14.46 Billion
Spear REIT Ltd JSE:SEA	South Africa	ZAC2.19 Billion
Shihlin Paper Corp TW:1903	Taiwan	NT$5.06 Billion
Shanghai Kai Kai Industry Co Ltd A SHG:600272	China	CN¥940.14 Million
Agro Tech Foods Limited NSE:ATFL	India	Rs1.33 Billion
Sarkuysan Elektrolitik Bakir Sanayi ve Ticaret AS IS:SARKY	Turkey	TL13.79 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Editas Medicine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Editas Medicine Inc asset portfolio.

Liquidity & Leverage Metrics

Editas Medicine Inc Total Liabilities Ratios Explained

Editas Medicine Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.25	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.56	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Editas Medicine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Editas Medicine Inc (2013–2025)

The table below shows the annual total liabilities of Editas Medicine Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	$159.25 Million	-23.19%
2024-12-31	$207.31 Million	+38.16%
2023-12-31	$150.06 Million	-2.33%
2022-12-31	$153.64 Million	+24.06%
2021-12-31	$123.84 Million	-30.82%
2020-12-31	$179.02 Million	-27.36%
2019-12-31	$246.45 Million	+33.78%
2018-12-31	$184.22 Million	+11.53%
2017-12-31	$165.18 Million	+74.66%
2016-12-31	$94.58 Million	-59.32%
2015-12-31	$232.48 Million	+745.99%
2014-12-31	$27.48 Million	+547.50%
2013-12-31	$4.24 Million	--

About Editas Medicine Inc

NASDAQ:EDIT USA Biotechnology

Market Cap

$365.52 Million

Market Cap Rank

#13670 Global

#3295 in USA

Share Price

$2.38

Change (1 day)

-4.99%

52-Week Range

$1.67 - $3.75

All Time High

$90.58